Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AK117 + Cadonilimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AK117 | AK 117|AK-117|Ligufalimab | CD47 Antibody 31 | AK117 is a monoclonal antibody that binds CD47, potentially resulting in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2020;8). | |
| Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06789848 | Phase II | AK117 + Cadonilimab | Ligufalimab and Cadonilimab in Advanced Liver Cancers | Recruiting | USA | 0 |